KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Change in Receivables: 2010-2022

Historic Change in Receivables for TherapeuticsMD (TXMD) over the last 12 years, with Sep 2022 value amounting to -$13.6 million.

  • TherapeuticsMD's Change in Receivables fell 439.82% to -$13.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$4.3 million, marking a year-over-year decrease of 130.19%. This contributed to the annual value of $4.3 million for FY2021, which is 47.39% down from last year.
  • As of Q3 2022, TherapeuticsMD's Change in Receivables stood at -$13.6 million, which was down 223.03% from $11.1 million recorded in Q2 2022.
  • In the past 5 years, TherapeuticsMD's Change in Receivables ranged from a high of $11.1 million in Q2 2022 and a low of -$13.6 million during Q3 2022.
  • For the 3-year period, TherapeuticsMD's Change in Receivables averaged around $864,273, with its median value being -$23,000 (2021).
  • In the last 5 years, TherapeuticsMD's Change in Receivables slumped by 2,767.32% in 2018 and then surged by 48,326.09% in 2022.
  • TherapeuticsMD's Change in Receivables (Quarterly) stood at -$1.8 million in 2018, then spiked by 629.91% to $9.3 million in 2019, then decreased by 7.40% to $8.6 million in 2020, then tumbled by 114.32% to -$1.2 million in 2021, then slumped by 439.82% to -$13.6 million in 2022.
  • Its Change in Receivables stands at -$13.6 million for Q3 2022, versus $11.1 million for Q2 2022 and -$489,000 for Q1 2022.